← All Traws Pharma, INC filings

Traws Pharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TRAW
Traws Pharma, INC
10-K/A: Traws Pharma Files 10-K/A for Part III Disclosures
Traws Pharma, Inc. filed an amendment to its 2025 Annual Report to provide required Part III corporate governance and executive compensation disclosures.
NASDAQ
TRAW
Traws Pharma, INC
10-K: Traws Pharma Reports 2025 Financials, Focuses on Viral Therapies
Traws Pharma, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing progress in its viral disease and oncology programs, alongside financial performance and future outlook.
NASDAQ
TRAW
Traws Pharma, INC
10-K/A: Traws Pharma Files Amendment to 10-K to Include Omitted Part III Information
Traws Pharma files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive officers, and corporate governance.
NASDAQ
TRAW
Traws Pharma, INC
10-K: Traws Pharma's 2024 10-K Filing: Merger, Pipeline Progress, and Financial Challenges
Traws Pharma's 2024 10-K reveals a year of transformation through a merger, pipeline advancement, and ongoing financial uncertainties.
NASDAQ
TRAW
Traws Pharma, INC
10-K/A: Traws Pharma Files Amended 10-K to Include Omitted Executive and Governance Details
Traws Pharma has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
TRAW
Traws Pharma, INC
10-K: Onconova Therapeutics Files 10-K, Outlines Progress in Cancer Drug Development
Onconova Therapeutics' 10-K filing details the company's ongoing clinical trials and financial status, highlighting the development of narazaciclib and rigosertib for cancer treatment.